tirzepatide ckd trial What Is Tirzepatide Used for? Approved and Potential Uses

Effects of tirzepatide on circulatory overload and end-organ damage in heart failure with preserved ejection fraction and obesity: a secondary analysis of the SUMMIT trial

26.34

★★★★☆4.8 (126)

CONFIDENCE trial: In persons with chronic kidney disease and type 2 diabetes, combination therapy with finerenone and empagliflozin led to a greater reduction in the urinary albumin-to-creatinine ratio than either drug alone

23.22

★★★★★4.9 (98)

Cardiovascular outcomes of semaglutide and tirzepatide for patients with type 2 diabetes in clinical practice

20.54

★★★★★5.0 (157)

SURPASS-4: Tirzepatide slows kidney disease in adults with type 2 diabetes, CV risk

20.46

★★★★★4.7 (84)

New Cleveland Clinic research finds tirzepatide is associated with a 16% lower risk of major heart and kidney complications compared with dulaglutide in people with Type 2 diabetes and heart disease. The

21.00

★★★★★4.9 (203)

GLP therapies have established themselves as kidney-protective in type 2 diabetes and high risk of kidney disease. This new post-hoc analysis of SURPASS-CVOT's kidney outcomes shows greater kidney protection with tirzepatide (#mounjaro)

20.60

★★★★★5.0 (176)

Eli Lilly still enrolling 4 Phase 3 trials for Tirzepatide: — SUMMIT=HFpEF TREASURE-CKD=Ob-T2DM-CKD SURMOUNT-OSA SURMOUNT-MMO=M&M in Obesity That's on top of the various other SURMOUNT trials that have already completed enrollment. ⬇️

29.42

★★★★★4.8 (132)